
Eli Lilly Weight Loss Drug has finally been launched in India. America’s famous pharma company Eli Lilly has launched a blockbuster drug named Mounjaro (tirzepatide) in India for people suffering from diabetes and obesity. This is the first drug made for both type 2 diabetes and obesity.
Talking about the year 2023, about 10 crore people in India were affected by obesity. Obesity is not just a problem. Rather it can become the root of more than 200 diseases. Which includes serious problems like heart diseases, blood pressure, stroke and cancer.
Apart from obesity, people in India are also troubled by the problem of diabetes. More than 10 crore people in India suffer from diabetes. In such a situation, there is good news for these people.
eli lilly weight loss drug approved in india
Let us tell you that this medicine will be available in the form of a single-dose vial. Let us tell you that it has also got approval from the Central Drugs Standard Control Organization (CDSCO). More than 10 crore people in India suffer from diabetes. In such a situation, the launch of this medicine is being considered a big achievement.
Talking about the price of Mounjaro-
- One vial of 2.5 mg – ₹3,500 (eli lilly weight loss drug cost)
- One vial of 5 mg – ₹4,375
This medicine has to be taken once a week. Which means that its cost can come from ₹14,000 to ₹17,500 in a month. However, how much dose to take will depend on the doctor’s advice. In the US, this medicine is available for $1,000–$1,200 i.e. around ₹86,000 to ₹1 lakh per month. According to this, it will be very cheap in India.
Why is Mounjaro cheap in India?
Eli Lilly says that it has kept the price of this drug low in India so that more and more people can take advantage of it. The demand for GLP-1 class drugs is increasing worldwide. Because they not only control blood sugar. But also help in reducing weight. The number of people affected by diabetes and obesity in India is increasing continuously. Due to which the need for this drug has become even more.
Will more cheap medicines come to India?
After the arrival of drugs like Mounjaro in the market, now Indian pharma companies are also preparing to enter this sector.
The patent of another drug called Semaglutide is going to expire in March 2026. After this, companies like Mankind Pharma, Alkem Labs and Dr. Reddy’s Laboratories can launch its cheaper version (generic version). This is expected to reduce the cost of treatment of diabetes and obesity further.
Increasing risk of obesity and diabetes
By 2023, about 10 crore people in India were affected by obesity. Obesity is not just a problem. Rather, it can become the root cause of more than 200 diseases. These include serious problems like heart diseases, blood pressure, stroke and cancer.